Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). | Vertex ...

Discover how Vertex Pharmaceuticals achieved 12% Q2 2025 revenue growth with new launches like ALYFTREK, CASGEVY, & JOURNAVX.

Section 1.10.32 of "de Finibus Bonorum et Malorum", written by Cicero in 45 BC ...

Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any ...

Vertex Pharmaceuticals (VRTX) reported $2.96 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 12.1%. EPS of $4.52 for the same period compares to -$12.83 a ...

Johnson & Johnson Vision professional affairs consultant, Nadia Siddiqi, outlines key considerations for locums when fitting ...

WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver ...

AI for enterprise is already here, helping companies streamline their operations, serve their customers better, and save ...

Shares of Vertex Pharmaceuticals sank 15% after the drugmaker announced a study showed its experimental pain medicine was not ...

Vertex Pharmaceuticals said on Monday it will not continue development of its experimental non-opioid painkiller as a solo ...

Vertex Pharmaceuticals ( NASDAQ: VRTX) shares fell in premarket trading on Tuesday after the company's VX-993 failed to meet ...